BioNTech SE filed a Form 6-K with the SEC on November 10, 2026, announcing that it has entered into an agreement to acquire a U.S. FDA Priority Review Voucher from Scholar Rock, Inc. for a total cash consideration of $205 million.

Key Highlights

  • Acquisition target: BioNTech agreed to acquire a U.S. Food and Drug Administration Priority Review Voucher from Scholar Rock, Inc. (NASDAQ:SRRK).
  • Total consideration: The total cash consideration for the PRV is $205 million, according to the filing.
  • Announcement date: The agreement was announced on November 10, 2026.
  • Signatories: The filing was signed by Ramon Zapata-Gomez, Chief Financial Officer, and Dr. Sierk Poetting, Chief Operating Officer, on behalf of BioNTech SE.
  • Exchange listing: BioNTech SE trades on NASDAQ:BNTX, as stated on the filing's cover.

BioNTech's $205 Million FDA Priority Review Voucher Purchase from Scholar Rock

According to the Form 6-K filed with the U.S. Securities and Exchange Commission, BioNTech SE (NASDAQ:BNTX) entered into an agreement to acquire a U.S. Food and Drug Administration Priority Review Voucher from Scholar Rock, Inc. (NASDAQ:SRRK). The filing states the total cash consideration for the transaction is $205 million. The announcement was made on November 10, 2026, the same date the report was submitted to the SEC.

The filing identifies the acquired asset as an FDA Priority Review Voucher, commonly referred to as a PRV. Such vouchers are issued by the FDA and can be used to obtain a priority review for a drug application or transferred to another party. The filing does not specify how BioNTech intends to apply the voucher, nor does it provide additional details about the transaction structure beyond the total cash consideration disclosed.

The 6-K was signed by Ramon Zapata-Gomez, identified as Chief Financial Officer, and Dr. Sierk Poetting, identified as Chief Operating Officer, both acting on behalf of BioNTech SE. BioNTech SE is headquartered at An der Goldgrube 12, D-55131 Mainz, Germany, and files annual reports under Form 20-F, as indicated on the cover of this report. A press release describing the transaction was included as Exhibit 99.1.

What Was Disclosed

BioNTech SE disclosed via a Form 6-K that it has agreed to acquire an FDA Priority Review Voucher from Scholar Rock, Inc. for $205 million in cash. The filing was dated November 10, 2026, and signed by the company's CFO and COO.